-$1.01 EPS Expected for Zogenix, Inc. (NASDAQ:ZGNX) This Quarter

Wall Street brokerages expect that Zogenix, Inc. (NASDAQ:ZGNX) will report earnings of ($1.01) per share for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Zogenix’s earnings, with the highest EPS estimate coming in at ($0.96) and the lowest estimate coming in at ($1.06). Zogenix reported earnings of ($0.95) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 6.3%. The company is expected to report its next quarterly earnings results on Thursday, November 5th.

According to Zacks, analysts expect that Zogenix will report full-year earnings of ($3.62) per share for the current year, with EPS estimates ranging from ($3.84) to ($3.29). For the next financial year, analysts anticipate that the company will post earnings of ($2.52) per share, with EPS estimates ranging from ($4.78) to ($1.30). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Zogenix.

Zogenix (NASDAQ:ZGNX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.96) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.02) by $0.06. The business had revenue of $1.03 million during the quarter, compared to analyst estimates of $1.10 million. Zogenix had a negative net margin of 8,758.48% and a negative return on equity of 53.91%.

Several research analysts recently issued reports on the stock. Raymond James assumed coverage on shares of Zogenix in a research note on Monday, August 24th. They issued a “market perform” rating for the company. Needham & Company LLC decreased their price target on shares of Zogenix from $50.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, June 26th. BidaskClub upgraded shares of Zogenix from a “strong sell” rating to a “sell” rating in a research note on Friday. Mizuho reiterated a “buy” rating and issued a $55.00 price target on shares of Zogenix in a research note on Thursday, August 6th. Finally, Zacks Investment Research lowered shares of Zogenix from a “buy” rating to a “hold” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $49.78.

Shares of Zogenix stock traded up $0.78 during trading on Friday, hitting $20.40. The company’s stock had a trading volume of 1,741,748 shares, compared to its average volume of 1,141,690. The company has a fifty day simple moving average of $21.19 and a two-hundred day simple moving average of $25.38. The company has a market capitalization of $1.13 billion, a PE ratio of -2.15 and a beta of 1.60. Zogenix has a 52 week low of $16.65 and a 52 week high of $57.22.

Large investors have recently added to or reduced their stakes in the business. US Bancorp DE increased its stake in Zogenix by 2,196.6% during the 1st quarter. US Bancorp DE now owns 1,332 shares of the company’s stock valued at $32,000 after purchasing an additional 1,274 shares in the last quarter. Glenmede Trust Co. NA purchased a new stake in shares of Zogenix during the 2nd quarter valued at about $32,000. Great West Life Assurance Co. Can boosted its holdings in shares of Zogenix by 47.8% during the 2nd quarter. Great West Life Assurance Co. Can now owns 3,945 shares of the company’s stock valued at $106,000 after acquiring an additional 1,275 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in shares of Zogenix by 35.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,910 shares of the company’s stock valued at $133,000 after acquiring an additional 1,284 shares during the last quarter. Finally, Bank of Montreal Can boosted its holdings in shares of Zogenix by 22.6% during the 2nd quarter. Bank of Montreal Can now owns 5,097 shares of the company’s stock valued at $141,000 after acquiring an additional 941 shares during the last quarter. Institutional investors and hedge funds own 96.57% of the company’s stock.

About Zogenix

Zogenix, Inc, a pharmaceutical company, develops and commercializes transformative therapies to enhance the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS); and which is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases.

Further Reading: How Do Front-End Loads Impact an Investment?

Get a free copy of the Zacks research report on Zogenix (ZGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.